UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2026
Commission file number: 001-36578
ENLIVEX LTD.
(Translation of registrant’s name into English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Securities Purchase Agreement
On November 14, 2026, Enlivex
Ltd., a company organized under the laws of the State of Israel (the “Company”), entered into a securities purchase
agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”), for the
purchase and sale, in a registered direct offering, of an aggregate of $7,500,000 of ordinary shares, par value NIS 96.00 per share, of
the Company (the “Ordinary Shares” and, such Ordinary Shares offered in the Registered Offering, the “Shares”)
(or pre-funded warrants in lieu thereof to purchase Ordinary Shares (the “Pre-Funded Warrants”)), together with accompanying
ordinary warrants to purchase up to an equal number of Ordinary Shares (the “Ordinary Warrants” and, together with
the Shares and the Pre-Funded Warrants, the “Securities”), at a combined purchase price of $1.315 per Share (or $1.314
per Pre-Funded Warrant) and accompanying Ordinary Warrant, representing a premium of 10.5% to the Nasdaq official closing price of the
Ordinary Shares on November 13, 2026 (the “Registered Offering”).
The Ordinary Warrants will have an exercise price of $1.578 per Ordinary
Share, will be exercisable immediately upon issuance and will expire three years from the initial closing date. The Pre-Funded Warrants
will have an exercise price of $0.001 per Ordinary Share, will be exercisable immediately upon issuance and will not expire until exercised
in full. To the extent that an Investor (together with its affiliates and any person acting as a group with such Investor or its affiliates)
would beneficially own in excess of 19.99% of the Ordinary Shares outstanding immediately after giving effect to the issuance of Shares
at any closing, such Investor will purchase Pre-Funded Warrants in lieu of the Shares that would result in such excess.
The Registered Offering will be consummated in a series of closings.
At the initial closing, which is expected to occur on or about November 17, 2026, subject to the satisfaction of customary closing conditions,
the Investors will purchase an aggregate of $500,000 of Securities. The Investors have also irrevocably committed, subject only to the
continued listing of the Ordinary Shares on Nasdaq or another U.S. national securities exchange, to purchase an additional aggregate $700,000
of Securities at each of 10 subsequent monthly closings, commencing on December 1, 2026 and ending on or about September 1, 2027, for
an aggregate of $7,000,000, at the same price and on the same terms as those applicable to the initial closing. Certain of the subsequent
closings may be postponed until the Company’s receipt of shareholder approval of an increase in its authorized share capital, and
any subsequent closing may be postponed if the Company’s registration statement or prospectus is not then available. The purchase
price may be paid in U.S. dollars, Tether (USDT) or a combination thereof.
The aggregate gross proceeds
to the Company from the Registered Offering are expected to be approximately $7.5 million, assuming all closings are consummated, before
deducting offering expenses payable by the Company and excluding any proceeds from the exercise of the Ordinary Warrants.
The Shares, Pre-Funded Warrants
and Ordinary Warrants offered in the Registered Offering, and the Ordinary Shares issuable upon exercise of such warrants, are being offered
by the Company pursuant to a shelf registration statement on Form F-3 (File No. 333-286956) previously filed with the Securities and Exchange
Commission (the “SEC”), which became effective on May 12, 2025.
In connection with the transactions,
the Company has also agreed to pay to certain Investors that meet a minimum subscription threshold, subject to the terms and conditions
of the Securities Purchase Agreement, (i) 5% of upfront payments, down payments, milestone payments and royalties received by the Company
or its subsidiaries, during the five years following the execution of the applicable transaction, from license, collaboration, partnership,
co-development, co-commercialization, distribution, supply and similar commercial transactions relating to its product candidates that
are entered into during the period commencing upon the Company’s receipt of the full $7.5 million subscription amount and ending
24 months following the date of the Securities Purchase Agreement, and (ii) 5% of the proceeds paid to the Company or its shareholders
from any sale, exclusive license or other disposition of the Company’s clinical assets during such 24-month period, subject to any
required shareholder approval. An Investor’s right to receive such payments will be forfeited if it fails to fund at least $850,000
of the aggregate subscription amount under the Securities Purchase Agreement.
The Securities Purchase Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company, other obligations of the parties and termination provisions.
On November 16, 2026, the
Company issued a press release announcing the Registered Offering, a copy of which is furnished as Exhibit 99.1 to this Report on Form
6-K.
The information contained
in this Report on Form 6-K (including the exhibit hereto) is hereby incorporated by reference into the Company’s registration statements
on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926, File No. 333-286956,
File No. 333-292417, File No. 333-294284, File No. 333-295215 and File No. 333-298071), filed with the SEC.
| Exhibit No. |
|
|
| 99.1 |
|
Press Release, dated November 16, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Enlivex Ltd. |
| |
(Registrant) |
| |
|
| |
By: |
/s/
Oren Hershkovitz |
| |
Name: |
Oren Hershkovitz |
| |
Title: |
Chief Executive Officer |
Date: November 16, 2026
Exhibit
99.1

Enlivex
Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nes-Ziona, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE)
-- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction
markets treasury, today announced that it has entered into a securities purchase agreement with certain investors for the purchase and
sale, in a registered direct offering, of an aggregate of $7,500,000 of the Company’s ordinary shares (or pre-funded warrants in
lieu thereof), together with accompanying ordinary warrants to purchase up to an equal number of ordinary shares, at a combined purchase
price of $1.315 per ordinary share (or $1.314 per pre-funded warrant) and accompanying ordinary warrant, representing a premium of 10.5%
to the Nasdaq official closing price of the ordinary shares on November 13, 2026 (the “Registered Offering”). The ordinary
warrants will have an exercise price of $1.578 per share, will be exercisable immediately upon issuance, and will expire three years from
the initial closing date. The pre-funded warrants will have an exercise price of $0.001 per share, will be exercisable immediately upon
issuance, and will not expire until exercised in full.
The Registered Offering will be consummated in
a series of closings. At the initial closing, which is expected to occur on or about November 17, 2026, subject to the satisfaction of
customary closing conditions, the investors will purchase an aggregate of $500,000 of securities. The investors have also irrevocably
committed, subject only to the continued listing of the ordinary shares on Nasdaq or another U.S. national securities exchange, to purchase
an additional aggregate of $700,000 of securities at each of ten subsequent monthly closings, commencing on December 1, 2026, and ending
on or about September 1, 2027, for an aggregate of $7,000,000, at the same price and on the same terms as those applicable to the initial
closing. Certain of the subsequent closings may be postponed until the Company’s receipt of shareholder approval of an increase
in its authorized share capital, and any subsequent closing may be postponed if the Company’s registration statement or prospectus
is not then available. The purchase price may be paid in U.S. dollars, USDT, or a combination thereof.
The aggregate gross proceeds to the Company from
the Registered Offering are expected to be approximately $7.5 million, assuming all closings are consummated, before deducting offering
expenses payable by the Company and excluding any proceeds from the exercise of the ordinary warrants. If the ordinary warrants issued
in the Registered Offering are exercised in full for cash, the Company would receive additional gross proceeds of approximately $9.0 million;
however, no assurance can be given that any of the ordinary warrants will be exercised. The Company intends to use the net proceeds from
the Registered Offering for clinical, regulatory, manufacturing, and research and development activities; potential acquisitions and in-licensing;
and other general corporate purposes. The Registered Offering is being made directly by the Company, without a placement agent, underwriter,
broker or dealer, and no placement agent fees will be payable.
The ordinary shares, pre-funded warrants and
ordinary warrants offered in the Registered Offering, and the ordinary shares issuable upon exercise of such warrants, are being offered
by the Company pursuant to a shelf registration statement on Form F-3 (File No. 333-286956) previously filed with the Securities and
Exchange Commission (the “SEC”), which became effective on May 12, 2025. The Registered Offering is being made only by means
of a prospectus supplement and accompanying base prospectus that form a part of the registration statement. A final prospectus supplement
and accompanying base prospectus relating to the Registered Offering will be filed with the SEC and, when filed, will be available on
the SEC’s website at www.sec.gov. Additional information regarding the securities described above and the terms of the transactions
will be included in a Report on Form 6-K to be filed by the Company with the SEC.
In connection with the transactions, the Company
has also agreed to pay to certain investors that meet a minimum subscription threshold, subject to the terms and conditions of the securities
purchase agreement, (i) 5% of upfront, down, milestone and royalty payments received by the Company or its subsidiaries during the five
years following execution, from license, collaboration, partnership, co-development, co-commercialization, distribution, supply and similar
commercial transactions relating to its product candidates that are entered into during the period commencing upon the Company’s
receipt of the full $7.5 million subscription amount and ending 24 months following the date of the securities purchase agreement, and
(ii) 5% of the proceeds paid to the Company or its shareholders from any sale, exclusive license or other disposition of the Company’s
clinical assets during such 24-month period, subject to any required shareholder approval. An investor’s right to receive such payments
will be forfeited if it fails to fund at least $850,000 of that aggregate subscription amount under the securities purchase agreement.
Greenberg Traurig, P.A. and FISCHER (FBC &
Co.) are serving as legal counsel to Enlivex.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.
ABOUT ENLIVEX
Enlivex is a quality longevity company powered
by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory
conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates
a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on
Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets
ecosystem.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,”
“will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,”
“intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,”
and other words of similar meaning, including statements relating to the expected timing and consummation of the initial closing and the
subsequent closings of the Registered Offering; the anticipated gross proceeds from, and the intended use of proceeds of, the Registered
Offering; the potential exercise of the ordinary warrants; the Company’s ability to obtain shareholder approval of an increase in
its authorized share capital; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by
the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings
and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity
of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s
plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position;
technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for
the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™
programs.
Each forward-looking statement contained in this
press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied
by such statement. Applicable risks and uncertainties include, among others, risks related to market conditions and the satisfaction of
closing conditions for the Registered Offering; the risk that one or more investors fail to fund their commitments at the subsequent closings;
the risk that the required shareholder approval is not obtained on a timely basis or at all; the risk of failure to realize the anticipated
benefits of the Registered Offering and the Company’s digital asset treasury strategy; changes in business, market, financial, political,
and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the
price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading
venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with
the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates;
risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating
to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s
filings with the SEC, including its most recent Annual Report on Form 20-F. The forward-looking statements in this press release speak
only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as
required by applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com